Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor.
PMID: 23099850
2013
The Journal of antimicrobial chemotherapy
Abstract: Seventeen NNRTI mutations have been associated with decreased susceptibility to rilpivirine: K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, H221Y, F227C, M230I/L, Y188L and the combination L100I + K103N.
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
PMID: 23361642
2013
The Journal of antimicrobial chemotherapy
Abstract: We studied the primary rilpivirine RAMs (K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, H221Y, F227C and M230I/L) and other potential rilpivirine-associated mutations (V90I, L100I, K101T, E138S, V179D/I, Y188L, V189I, G190A/E/S and M230V).
Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals.
PMID: 23443042
2013
Journal of the International AIDS Society
Table: Y188L
Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series.
PMID: 23545531
2013
Antimicrobial agents and chemotherapy
Abstract: The antiviral potency of compound A was unaffected by the presence of nonnucleotide RT inhibitor (NNRTI) mutations tested (L100I, K103N/Y181C, V106A, or Y188L).
Description of HIV-1 group M molecular epidemiology and drug resistance prevalence in Equatorial Guinea from migrants in Spain.
Abstract: Transmitted drug-resistance (TDR) rate among naive patients attended in Spain (n = 144) was 4.7%: 3.4% for PI (all with M46IL), 1.8% for NRTI (all with M184V) and 0.9% for NNRTI (Y188L).
Table: Y188L
Evaluation of WHO immunologic criteria for treatment failure: implications for detection of virologic failure, evolution of drug resistance and choice of second-line therapy in India.
PMID: 23735817
2013
Journal of the International AIDS Society
Method: Non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations that we assessed included K103N, Y181C, Y181I, G190A, G190S, V108I, Y188L, V106M, K103NS, K101E and G190E.
Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.
Method: Different RT mutations at the same residue were pooled, including the NRTI-resistance mutations D67NG, K70EGQ, L74VI, M184VI, T215YF, K219QE and the NNRTI-resistance mutations K101EH, K103NS, Y188LCH, and G190ASEQ.
Pyridones as NNRTIs against HIV-1 mutants: 3D-QSAR and protein informatics.
PMID: 23884707
2013
Journal of computer-aided molecular design
Abstract: CoMFA and CoMSIA based 3D-QSAR of HIV-1 RT wild and mutant (K103, Y181C, and Y188L) inhibitory activities of 4-benzyl/benzoyl pyridin-2-ones followed by protein informatics of corresponding non-nucleoside inhibitors' binding pockets from pdbs 2BAN, 3MED, 1JKH, and 2YNF were analysed to discover consensus features of the compounds for broad-spectrum activity.
Persistence of HIV-1 transmitted drug resistance mutations.
PMID: 23904291
2013
The Journal of infectious diseases
Table: Y188L
Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis.
Result: Four weeks after delivery, wild-type NVP-R susceptible virus was nearly replaced with variants carrying individual non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistance mutations such as K103N, V106M, Y188L and G190A, and importantly, the generation of a major clonally-amplified variant carrying K103N mutation in the mammary gland compartment (Figure 3).
Figure: Point mutations numbered 1-4 are as follows: 1 for K103N, 2 for V106M, 3 for Y188C/L, 4 for G190A.
HIV mutation literature information.
PMID: 
2013
The Journal of antimicrobial chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT